# Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study

> **NCT04252612** · EARLY_PHASE1 · WITHDRAWN · sponsor: **H. Lee Moffitt Cancer Center and Research Institute**

## Conditions studied

- Cutaneous Squamous Cell Carcinoma

## Interventions

- **DRUG:** Pramlintide

## Key facts

- **NCT ID:** NCT04252612
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-01-30
- **Primary completion:** 2023-06-26
- **Final completion:** 2023-06-26
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Poor accrual
- **Last updated:** 2023-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04252612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04252612, "Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04252612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*